Sanna Enrico, Manzione Ana Maria, Mingozzi Silvia, Biancone Luigi
SC Nefrologia, Dialisi, Trapianto di Rene, Città della Salute e della Scienza di Torino, sede Molinette, Torino, Italia.
G Ital Nefrol. 2023 Oct 3;40(Suppl 81):2023-S81.
Onconephrology, an emerging field in modern medicine, is gaining importance due to its intricate challenges derived from the mixing field of tumorous and renal diseases. The growing incidence of tumors in transplant patients requires preventive strategies and accurate monitoring. Pre-transplant screening is crucial, focusing on subjects with oncological history. Post-transplant follow-up must be personalized, tailoring screenings for patients with cancer history. Immunosuppressive therapy, although essential to prevent organ rejection, represents a delicate balance between controlling the immune response and cancer risk management. Immune checkpoint inhibitors emerge as a fascinating potential for cancer therapy, but their use in transplant patients requires caution and further research to carefully evaluate their safety and effectiveness, balancing potential benefits with actual risk of rejection. In summary, onconephrology is a growing field that requires an interdisciplinary approach and constant research, aimed at successfully addressing the complex challenges associated with oncological diseases in renal and transplant patients.
肿瘤肾脏病学是现代医学中一个新兴的领域,由于其源于肿瘤和肾脏疾病混合领域的复杂挑战而日益重要。移植患者中肿瘤发病率的不断上升需要预防策略和精确监测。移植前筛查至关重要,重点关注有肿瘤病史的患者。移植后随访必须个性化,为有癌症病史的患者量身定制筛查方案。免疫抑制疗法虽然对于预防器官排斥至关重要,但在控制免疫反应和癌症风险管理之间代表着一种微妙的平衡。免疫检查点抑制剂作为癌症治疗的一个引人入胜的潜在手段出现,但它们在移植患者中的使用需要谨慎并进一步研究,以仔细评估其安全性和有效性,平衡潜在益处与实际排斥风险。总之,肿瘤肾脏病学是一个不断发展的领域,需要跨学科方法和持续研究,旨在成功应对与肾脏和移植患者肿瘤疾病相关的复杂挑战。